Poseida Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$336.5M
Lead Investor(s):Longitude Capital

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Poseida Therapeutics's estimated annual revenue is currently $32.6M per year.(?)
  • Poseida Therapeutics received $30.0M in venture funding in April 2018.
  • Poseida Therapeutics's estimated revenue per employee is $155,000
  • Poseida Therapeutics's total funding is $336.5M.

Employee Data

  • Poseida Therapeutics has 210 Employees.(?)
  • Poseida Therapeutics grew their employee count by 38% last year.
  • Poseida Therapeutics currently has 42 job openings.

Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac DNA Modification System, TAL-CLOVER and Cas-CLOVER site-specific nucleases, and Footprint-Free Gene Editing (FFGE). For more information, visit www.poseida.com.